Cocrystal Pharma Inc (COCP) 0.5725 $COCP
Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.05 (-0.23)
Cocrystal Pharma Announces Filing 2016 First Quarter Financial Statements and Provides Company Update
Marketwired - Wed May 11, 6:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - May 11, 2016) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending March 31, 2016 and provided an update on the Phase Ia/Ib clinical study of CC-31244.
OPK: 9.05 (-0.23)
Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 36.94 (-0.45), COOL: 0.80 (-0.02), OPK: 9.05 (-0.23), CDXC: 4.98 (-0.09), TEVA: 52.01 (-0.20), MJCO: 5.12 (-0.16)
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects
Marketwired - Mon Apr 25, 7:01AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it has initiated a Phase Ia/Ib clinical study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is currently enrolling subjects and has dosed the first subject with no serious adverse events reported.
OPK: 9.05 (-0.23)
Retrophin Names Gary A. Lyons Chairman of the Board of Directors
GlobeNewswire - Mon Apr 04, 3:30PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced Gary A. Lyons will become the Company's next independent Chairman of the Board of Directors, effective at the conclusion of the annual meeting of stockholders, to be held on May 18, 2016. Mr. Lyons, an independent director of Retrophin since 2014, will succeed current Chairman Jeffrey A. Meckler. Mr. Meckler, who was appointed chief executive officer of Cocrystal Pharma, Inc. in October 2015, will remain on the Board as an independent director.
RTRX: 17.34 (-0.12)
CORRECTION - Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update
Marketwired - Wed Mar 16, 8:59AM CDT
In the news release, "Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update" issued Tuesday, March 15, 2016 by Cocrystal Pharma, Inc. (OTCQB: COCP), we are advised by the company that the fifth paragraph should now read "During the fourth quarter, General and Administrative (SG&A) cash expenses were $2.0 million for 2015 compared to $0.3 million for 2014. The increase of $1.7 million was due to compensation related costs, and professional service costs related to being a public company. In addition, the Company incurred non-cash charges related to stock options of $0.9 million." Complete corrected text follows.
OPK: 9.05 (-0.23)
Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update
Marketwired - Tue Mar 15, 4:47PM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing on Form 10-K of its financial results for the fourth quarter and year ended December 31, 2015, and provided a research and development update.
OPK: 9.05 (-0.23)
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.86 (+0.06), CDXC: 4.98 (-0.09)
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.86 (+0.06), CDXC: 4.98 (-0.09)
Cocrystal Pharma to Present at Two Upcoming Investor Conferences
Marketwired - Wed Mar 09, 6:30AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced that Jeffery Meckler, Chief Executive Officer, and Douglas Mayers, M.D., Chief Medical Officer, will present a corporate overview at the 28th Annual ROTH Conference and the Barclays Capital Global Healthcare Conference.
OPK: 9.05 (-0.23)
Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus
Marketwired - Wed Feb 10, 7:02AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today it has signed an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV).
OPK: 9.05 (-0.23)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.61 (-0.19), CLDX: 4.27 (-0.14), BMY: 70.67 (-1.06)
Global Gastroenteritis Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/56wkzd/gastroenteritis) has announced the addition of the "Gastroenteritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastroenteritis Overview - Therapeutics Development - Pipeline Products for Gastroenteritis - Overview - Pipeline Products for Gastroenteritis - Comparative Analysis - Gastroenteritis - Therapeutics under Development by Companies - Gastroenteritis - Therapeutics under Investigation by Universities/Institutes - Gastroenteritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Gastroenteritis - Products under Development by Companies - Gastroenteritis - Products under Investigation by Universities/Institutes - Gastroenteritis - Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Nanotherapeutics, Inc. - RedHill Biopharma Ltd. - Takeda Pharmaceutical Company Limited - UMN Pharma Inc. For more information visit http://www.researchandmarkets.com/research/56...oenteritis
RDHL: 10.10 (-0.83)
Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.05 (-0.23)
Cocrystal Pharma Announces Filing 2016 First Quarter Financial Statements and Provides Company Update
Marketwired - Wed May 11, 6:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - May 11, 2016) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending March 31, 2016 and provided an update on the Phase Ia/Ib clinical study of CC-31244.
OPK: 9.05 (-0.23)
Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 36.94 (-0.45), COOL: 0.80 (-0.02), OPK: 9.05 (-0.23), CDXC: 4.98 (-0.09), TEVA: 52.01 (-0.20), MJCO: 5.12 (-0.16)
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects
Marketwired - Mon Apr 25, 7:01AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it has initiated a Phase Ia/Ib clinical study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is currently enrolling subjects and has dosed the first subject with no serious adverse events reported.
OPK: 9.05 (-0.23)
Retrophin Names Gary A. Lyons Chairman of the Board of Directors
GlobeNewswire - Mon Apr 04, 3:30PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced Gary A. Lyons will become the Company's next independent Chairman of the Board of Directors, effective at the conclusion of the annual meeting of stockholders, to be held on May 18, 2016. Mr. Lyons, an independent director of Retrophin since 2014, will succeed current Chairman Jeffrey A. Meckler. Mr. Meckler, who was appointed chief executive officer of Cocrystal Pharma, Inc. in October 2015, will remain on the Board as an independent director.
RTRX: 17.34 (-0.12)
CORRECTION - Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update
Marketwired - Wed Mar 16, 8:59AM CDT
In the news release, "Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update" issued Tuesday, March 15, 2016 by Cocrystal Pharma, Inc. (OTCQB: COCP), we are advised by the company that the fifth paragraph should now read "During the fourth quarter, General and Administrative (SG&A) cash expenses were $2.0 million for 2015 compared to $0.3 million for 2014. The increase of $1.7 million was due to compensation related costs, and professional service costs related to being a public company. In addition, the Company incurred non-cash charges related to stock options of $0.9 million." Complete corrected text follows.
OPK: 9.05 (-0.23)
Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2015 and Provides Company Update
Marketwired - Tue Mar 15, 4:47PM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing on Form 10-K of its financial results for the fourth quarter and year ended December 31, 2015, and provided a research and development update.
OPK: 9.05 (-0.23)
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.86 (+0.06), CDXC: 4.98 (-0.09)
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.86 (+0.06), CDXC: 4.98 (-0.09)
Cocrystal Pharma to Present at Two Upcoming Investor Conferences
Marketwired - Wed Mar 09, 6:30AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced that Jeffery Meckler, Chief Executive Officer, and Douglas Mayers, M.D., Chief Medical Officer, will present a corporate overview at the 28th Annual ROTH Conference and the Barclays Capital Global Healthcare Conference.
OPK: 9.05 (-0.23)
Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus
Marketwired - Wed Feb 10, 7:02AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today it has signed an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV).
OPK: 9.05 (-0.23)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.61 (-0.19), CLDX: 4.27 (-0.14), BMY: 70.67 (-1.06)
Global Gastroenteritis Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/56wkzd/gastroenteritis) has announced the addition of the "Gastroenteritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastroenteritis Overview - Therapeutics Development - Pipeline Products for Gastroenteritis - Overview - Pipeline Products for Gastroenteritis - Comparative Analysis - Gastroenteritis - Therapeutics under Development by Companies - Gastroenteritis - Therapeutics under Investigation by Universities/Institutes - Gastroenteritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Gastroenteritis - Products under Development by Companies - Gastroenteritis - Products under Investigation by Universities/Institutes - Gastroenteritis - Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Nanotherapeutics, Inc. - RedHill Biopharma Ltd. - Takeda Pharmaceutical Company Limited - UMN Pharma Inc. For more information visit http://www.researchandmarkets.com/research/56...oenteritis
RDHL: 10.10 (-0.83)
